Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Jiangsu Lianhuan Pharmaceutical Yönetim

Yönetim kriter kontrolleri 4/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

Ben Niu

İcra Kurulu Başkanı

CN¥709.8k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.6yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Profits Appear To Have Quality Issues

Sep 11

We Think That There Are More Issues For Jiangsu Lianhuan Pharmaceutical (SHSE:600513) Than Just Sluggish Earnings

Mar 12

CEO

Ben Niu (42 yo)

1.6yrs

Görev süresi

CN¥709,800

Tazminat

Mr. Ben Niu serves as Chief Engineer at Jiangsu Lianhuan Pharmaceutical Co., Ltd. since May 22, 2020 and serves as its General Manager since March 8, 2023.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ben Niu	Chief Engineer & GM	1.6yrs	CN¥709.80k	Veri yok
Heping Pan	Vice Chairman	3.5yrs	CN¥731.20k	Veri yok
Wen Tao Huang	Secretary of the Board of Directors	6.4yrs	CN¥657.20k	Veri yok
Zhou Jun	Deputy General Manager	no data	CN¥732.10k	Veri yok
Yi Shen	Deputy General Manager	no data	CN¥674.60k	Veri yok
Yong Jun Zhu	Deputy General Manager	no data	CN¥666.50k	Veri yok

3.5yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 600513's management team is considered experienced (3.5 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Heping Pan	Vice Chairman	3.5yrs	CN¥731.20k	Veri yok
Chunlai Xia	Director	8.5yrs	Veri yok	Veri yok
Wenge Wu	Chairman	10.4yrs	CN¥829.20k	Veri yok
Guangji Wang	Director	6.2yrs	Veri yok	Veri yok
Zhen Hua Qian	Director	6.4yrs	CN¥760.30k	Veri yok
Ying Chen	Independent Director	5.2yrs	CN¥80.00k	Veri yok
Bin Zhang	Independent Director	4.4yrs	CN¥80.00k	Veri yok
Jing Zhang	Employee Supervisor	3.5yrs	Veri yok	Veri yok
Baochang Yu	Chairman of the Supervisory Board	3.5yrs	Veri yok	Veri yok
Chunyuan Wang	Supervisor	3.5yrs	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 600513's board of directors are considered experienced (4.8 years average tenure).

Jiangsu Lianhuan Pharmaceutical Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Jiangsu Lianhuan Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 17%

Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Profits Appear To Have Quality Issues

New major risk - Financial position

Second quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.10 in 2Q 2023)

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dividend of CN¥0.15 announced

First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.11 in 1Q 2023)

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

We Think That There Are More Issues For Jiangsu Lianhuan Pharmaceutical (SHSE:600513) Than Just Sluggish Earnings

Jiangsu Lianhuan Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.49 in FY 2022)

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 20%

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 06, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Third quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.12 in 3Q 2022)

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Second quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.12 in 2Q 2022)

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 26, 2023

First quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.11 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.41 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.11 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.10 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.09 in 1Q 2021)

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.12 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.089 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.07 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.36 (vs CN¥0.28 in FY 2019)

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥8.73

Investor sentiment deteriorated over the past week

New 90-day low: CN¥9.96

New 90-day low: CN¥9.99

Third quarter earnings released

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

Earnings released

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 22, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş